F.P. Gaube , C. Behzadi , W. Böcker , H. Polzer , S.F. Baumbach
{"title":"Knochenmarködem – Ätiologie und Behandlung","authors":"F.P. Gaube , C. Behzadi , W. Böcker , H. Polzer , S.F. Baumbach","doi":"10.1016/j.fuspru.2025.01.004","DOIUrl":null,"url":null,"abstract":"<div><div>Over the last decades, there has been a significant increase in the diagnosis of „bone marrow edema“ (BME). BME is primarily a radiological-descriptive term. It can be caused by a variety of physiological and pathophysiological processes. This narrative review aims to present a standardized diagnostic algorithm and summarize the existing evidence on adjunctive therapies.</div><div>The diagnostic algorithm is based on a sequential diagnostic approach, which includes MRI, X-ray/CT, basic laboratory tests, a detailed endocrinological laboratory workup, and DXA. This sequential process addresses traumatic, inflammatory, septic, mechanical/degenerative, ischemic/neurogenic, neoplastic, and metabolic causes of BME. Only when no specific cause has been identified, the BME should be classified as a bone marrow edema syndrome (BMES).</div><div>The cornerstone of BME therapy is identifying and treating the underlying pathology. Only by addressing the cause long-term recovery can be achieved. In addition to treating the primary disease—or in cases of isolated BMES—adjunctive conservative therapies (e.g., NSAIDs ± immobilization ± partial weight-bearing, shockwave therapy, pulsed electromagnetic fields) or pharmacological treatments (e.g., bisphosphonates or iloprost) may be considered. All pharmacological treatments are off-label and therefore require an informed consent. According to the authors, surgical treatment is not part of BME Management.</div></div>","PeriodicalId":39776,"journal":{"name":"Fuss und Sprunggelenk","volume":"23 1","pages":"Pages 2-14"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fuss und Sprunggelenk","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1619998725000042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Over the last decades, there has been a significant increase in the diagnosis of „bone marrow edema“ (BME). BME is primarily a radiological-descriptive term. It can be caused by a variety of physiological and pathophysiological processes. This narrative review aims to present a standardized diagnostic algorithm and summarize the existing evidence on adjunctive therapies.
The diagnostic algorithm is based on a sequential diagnostic approach, which includes MRI, X-ray/CT, basic laboratory tests, a detailed endocrinological laboratory workup, and DXA. This sequential process addresses traumatic, inflammatory, septic, mechanical/degenerative, ischemic/neurogenic, neoplastic, and metabolic causes of BME. Only when no specific cause has been identified, the BME should be classified as a bone marrow edema syndrome (BMES).
The cornerstone of BME therapy is identifying and treating the underlying pathology. Only by addressing the cause long-term recovery can be achieved. In addition to treating the primary disease—or in cases of isolated BMES—adjunctive conservative therapies (e.g., NSAIDs ± immobilization ± partial weight-bearing, shockwave therapy, pulsed electromagnetic fields) or pharmacological treatments (e.g., bisphosphonates or iloprost) may be considered. All pharmacological treatments are off-label and therefore require an informed consent. According to the authors, surgical treatment is not part of BME Management.